Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.eortc.be

Clinical Trials

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Phase 2

Active, not recruiting

Conditions: Unresectable Stage III Melanoma
Stage IV Melanoma

Interventions: Drug: Nivolumab + Ipilimumab
Drug: Encorafenib + Binimetinib

First Posted Date: 2017-08-01

Last Posted Date: 2024-05-29

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 271

Registration Number: NCT03235245

Locations: 🇩🇰
University Hospitals Copenhagen - Herlev Hospital - University Copenhagen, Herlev, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark
🇫🇮
Helsinki University Central Hospital - Dept of Oncology, Helsinki, Finland

and more 35 locations

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma

Phase 1

Completed

Conditions: Astrocytoma, Grade III
Glioblastoma

Interventions: Drug: TG02
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2017-07-21

Last Posted Date: 2022-05-31

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 71

Registration Number: NCT03224104

Locations: 🇦🇹
Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH uniklinieken, Vienna, Austria
🇫🇷
CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France
🇫🇷
CHRU de Lille, Lille, France

and more 7 locations

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Phase 2

Active, not recruiting

Conditions: Thymoma Type B3
Thymic Carcinoma

Interventions: Drug: Nivolumab

First Posted Date: 2017-04-28

Last Posted Date: 2023-02-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 55

Registration Number: NCT03134118

Locations: 🇧🇪
Institut Jules Bordet, Brussel, Belgium
🇧🇪
Universitair Ziekenhuis Antwerpen (UZA), Edegem, Belgium
🇫🇷
CHU de Brest, Brest, France

and more 17 locations

Synergism of Immunomodulation and Tumor Ablation

Phase 2

Completed

Conditions: Colorectal Cancer
Liver Metastases

Interventions: Drug: Durvalumab (MEDI4736)
Drug: Tremelimumab
Radiation: Sterotactic body radiation therapy (SBRT)
Other: Radiofrequency ablation (RFA)

First Posted Date: 2017-04-05

Last Posted Date: 2022-05-31

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 22

Registration Number: NCT03101475

Locations: 🇦🇹
Medical University Vienna - General Hospital AKH, Vienna, Austria
🇫🇷
Institut Bergonie, Bordeaux, France
🇩🇪
Universitaetsklinikum Carl Gustav Carus, Dresden, Germany

and more 7 locations

Biomarker-based Study in R/M SCCHN

Phase 2

Active, not recruiting

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: Niraparib
Drug: INCAGN01876
Drug: IPH2201
Drug: Afatinib
Drug: Palbociclib
Drug: standard of care
Drug: Durvalumab

First Posted Date: 2017-03-23

Last Posted Date: 2023-11-03

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 340

Registration Number: NCT03088059

Locations: 🇧🇪
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussel, Belgium
🇧🇪
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussel, Belgium

and more 30 locations

Lenvatinib in Second Line Endometrial Carcinoma

Phase 2

Withdrawn

Conditions: Endometrial Neoplasms

Interventions: Drug: Doxorubicin
Drug: Lenvatinib

First Posted Date: 2016-12-29

Last Posted Date: 2016-12-29

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT03005015

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma

Not Applicable

Active, not recruiting

Conditions: Oropharyngeal Cancer
Supraglottic Squamous Cell Carcinoma
Hypopharyngeal Squamous Cell Carcinoma

First Posted Date: 2016-12-06

Last Posted Date: 2025-05-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 112

Registration Number: NCT02984410

Locations: 🇧🇪
CHU-UCL Namur - CHU Mont Godinne, Namur, Yvoir, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪
Institut Jules Bordet-Hopital Universitaire ULB, Brussels, Belgium

and more 29 locations

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: ADT
Drug: ODM-201

First Posted Date: 2016-11-23

Last Posted Date: 2024-04-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 61

Registration Number: NCT02972060

Locations: 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium

and more 9 locations

Trabectedin Maintenance Post 1st-line in STS

Phase 3

Terminated

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Trabectedin

First Posted Date: 2016-10-11

Last Posted Date: 2020-09-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 13

Registration Number: NCT02929394

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 11 locations

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Phase 2

Active, not recruiting

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Placebo
Drug: Nintedanib

First Posted Date: 2016-08-11

Last Posted Date: 2024-04-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 37

Registration Number: NCT02863055

Locations: 🇧🇪
UZ Antwerpen, Antwerpen, Belgium
🇧🇪
UZ Gent, Gent, Belgium
🇮🇹
Ospedale San Paolo, Milan, Italy

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy